Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy
暂无分享,去创建一个
F. Garrido | L. Real | F. Ruiz-Cabello | T. Cabrera | J. M. Romero | I. Maleno | R. Carretero | F. Rodríguez | F. Camacho | F. Rodriguez
[1] G. Pawelec,et al. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines , 2008, Cancer Immunology, Immunotherapy.
[2] D. Morton,et al. Vaccine therapy for melanoma: current status and future directions. , 2007, Vaccine.
[3] F. Garrido,et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination , 2007, Cancer Immunology, Immunotherapy.
[4] F. Garrido,et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines , 2007, BMC Cancer.
[5] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[6] F. Garrido,et al. LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas , 2006, Immunogenetics.
[7] I. Ellis,et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer , 2005, International journal of cancer.
[8] F. Lozupone,et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? , 2005, Expert opinion on biological therapy.
[9] S. Menzies,et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma , 2005, Cancer Immunology, Immunotherapy.
[10] F. Garrido,et al. Involvement of the chaperone tapasin in HLA‐B44 allelic losses in colorectal tumors , 2005, International journal of cancer.
[11] P. Coulie,et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Rosenberg,et al. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Paul,et al. Gene-based vaccines and immunotherapeutics , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] P. Slootweg,et al. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis. , 2004, Tissue antigens.
[15] D. Berd. M-Vax: an autologous, hapten-modified vaccine for human cancer , 2004, Expert review of vaccines.
[16] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[17] R. Rees,et al. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression , 2004, Cancer Immunology, Immunotherapy.
[18] Federico Garrido,et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape , 2004, Cancer Immunology, Immunotherapy.
[19] F. Garrido,et al. Multiple mechanisms are responsible for the alteration in the expression of HLA class I antigens in melanoma , 2003 .
[20] Euijae Kim,et al. A Single Polymorphic Residue Within the Peptide-Binding Cleft of MHC Class I Molecules Determines Spectrum of Tapasin Dependence , 2003, The Journal of Immunology.
[21] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[22] Jonathan J. Lewis,et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Dalerba,et al. Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.
[24] S. Markovic,et al. Challenges in the development of effective peptide vaccines for cancer. , 2002, Mayo Clinic proceedings.
[25] B. Seliger,et al. HLA class I antigen abnormalities and immune escape by malignant cells. , 2002, Seminars in cancer biology.
[26] F. Garrido,et al. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. , 2001, Tissue antigens.
[27] P. Coulie,et al. Biological and clinical developments in melanoma vaccines , 2001, Expert opinion on biological therapy.
[28] M. Gore,et al. Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC) , 2000, Clinical and experimental immunology.
[29] S. Pettit,et al. Selection of metastatic tumour phenotypes by host immune systems , 1999, The Lancet.
[30] M. Griffioen,et al. Role of the interferon-stimulated response element in HLA-B downregulation in human melanoma cell lines , 1999, Immunogenetics.
[31] F. Brasseur,et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.
[32] F. Garrido,et al. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line , 1998, Cancer Immunology, Immunotherapy.
[33] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[34] F. Marincola,et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. , 1994, Journal of immunology.
[35] J U Gutterman,et al. Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Vilella,et al. Biochemical and serological characterization of a public antigenic determinant present on HLA-B molecules. , 1990, Tissue antigens.
[37] H. Ploegh,et al. Suppression of class I human histocompatibility leukocyte antigen by c- myc is locus specific , 1989, The Journal of experimental medicine.
[38] F. Esteban,et al. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. , 1989, British Journal of Cancer.
[39] H. Ploegh,et al. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. , 1986, Journal of immunology.
[40] J. Strominger,et al. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131 , 1985, The Journal of experimental medicine.
[41] F. Garrido,et al. Role of altered expression of HLA class I molecules in cancer progression. , 2007, Advances in experimental medicine and biology.
[42] F. Garrido,et al. MHC class I antigens and immune surveillance in transformed cells. , 2007, International review of cytology.
[43] I. Ellis,et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.
[44] R. Vilella,et al. Identification of the amino acid residues defining an intralocus determinant in the α1 domain of HLA-A molecules , 2006, Immunogenetics.
[45] F. Garrido,et al. Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.
[46] F. Garrido,et al. MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.
[47] L. Schuchter,et al. Metastatic melanoma , 2001, Current treatment options in oncology.
[48] F. Garrido,et al. MHC antigens and malignancy. , 1986, Nature.